The detection of drug-drug interactions (DDIs) is a crucial task for drug safety surveillance,
which provides effective and safe co-prescriptions of multiple drugs. Since laboratory …

Drug–drug interactions (DDIs) constitute an important concern in drug development and
postmarketing pharmacovigilance. They are considered the cause of many adverse drug …

Introduction Pharmacovigilance programs protect patient health and safety by identifying
adverse event signals through postmarketing surveillance of claims data and spontaneous …

With increasing trend of polypharmacy, drug‐drug interaction (DDI)‐induced adverse drug
events (ADEs) are considered as a major challenge for clinical practice. As premarketing …

Polypharmacy increases the risk of drug–drug interactions (DDIs). Combining
epidemiological studies with pharmacokinetic modeling, we detected and evaluated high …

It is widely accepted that molecular reductionist views of highly complex human physiologic
activity, eg, the aging process, as well as therapeutic drug efficacy are largely …

Drug interaction is a leading cause of adverse drug events and a major obstacle for current
clinical practice. Pharmacovigilance data mining, pharmacokinetic modeling, and text …

Mining high-order drug-drug interaction (DDI) induced adverse drug effects from electronic
health record databases is an emerging area, and very few studies have explored the …

We propose to study a novel pharmacovigilance problem for mining directional effects of
high‐order drug interactions on an adverse drug event (ADE). Our goal is to estimate each …

Drug‐drug interactions (DDIs) are a common cause of adverse drug events (ADEs). The
electronic medical record (EMR) database and the FDA's adverse event reporting system …